2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
40
Gastro-enteropancreatic neuroendocrine tumor
8
Paraganglioma
6
Meningioma
6
Pheochromocytoma
5
Carcinoma, Neuroendocrine
4
Neuroblastoma
3
Carcinoid Tumor
3
Adenoma, Islet Cell
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms
2
Medulloblastoma
2
Glioma
2
Glioblastoma
2
Carcinoma, Merkel Cell
2
Carcinoma, Medullary
2
Stomach Neoplasms
1
Somatostatinoma
1
Somatostatin Receptor-positive Neuroendocrine Tumor
1
Somatostatin Receptor-positive GEP-NET
1
Small Cell Lung Carcinoma
1
Serotonin Syndrome
1
Sarcoma, Synovial
1
Recurrence
1
Pituitary Neoplasms
1
Parathyroid Neoplasms
1
Pancreatic Diseases
1
Osteosarcoma
1
Interventions
Ifosfamide
30
Methotrexate
29
Doxorubicin
26
Cyclophosphamide
24
Cisplatin
22
Filgrastim
18
Etoposide
17
Gemcitabine
16
Leucovorin
14
Magnetic Resonance Spectroscopy
11
Temozolomide
10
Specimen Handling
10
cabozantinib
9
apatinib
9
X-Rays
9
Carboplatin
9
fludarabine
8
Radiotherapy
8
Nivolumab
8
Neoadjuvant Therapy
8
Irinotecan
8
Granulocyte Colony-Stimulating Factor
8
Drug Therapy
8
Docetaxel
8
Zoledronic Acid
7
Vincristine
7
Sirolimus
7
Phantoms, Imaging
7
Biopsy
7
mifamurtide
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Osteosarcoma
×
lutetium Lu 177 dotatate
×
Clear all
NCT06607692
2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled